Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Wealth planning tools are essential for financial success. Discover resources that can help you achieve your financial aspirations.
28,655 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Goldman Sachs' latest research paints a paradox: trillions are pouring into AI infrastructure, but returns remain mur...
The BOAT ETF has surged on shipping-rate momentum tied to Strait of Hormuz tensions, yet quarterly payouts swing with...
Inflation soaring again, this under-the-radar ETF is quietly drawing interest from investors seeking an edge against ...
Micron reports robust Q3 guidance and signs a five-year strategic deal, fueling optimism that the AI memory cycle cou...
Public tours of Jim Henson's Creature Shop in Queens reveal the hidden craft behind Kermit and friends. The 80-minute...
As markets wobble toward summer, defensive bets like the Vanguard Consumer Staples Index ETF offer ballast. Learn why...
As Brazil debates new export taxes, ECOW’s big distributions spotlight a yield that may hide political and commodity ...
June 2026 shifts spotlight to Tesla and BYD as margin rebound meets policy tailwinds. Here’s the latest data and what...
A fresh investing approach blends emerging-market debt with high-quality short bonds to deliver higher income and ste...
Lyft’s leadership introduces a multi-sensor safety standard for autonomous rides, positioning safety at the center as...
In late June 2026, XRP and XLM are both testing breakout attempts after weeks of consolidation. Neither has confirmed...